Pharvaris successfully concludes Phase I study

Pharvaris, a clinical-stage biopharmaceutical company, has concluded a clinical Phase I study for PHA121 with promising results. The oral drug to treat hereditary angioedema (HAE) has proven to be safe and tolerated, as the Zug-based firm with subsidiaries in the Netherlands and the USA recently announced in a press release.

The start-up’s activities are focused on oral bradykinin-B2-receptor antagonists. It is developing alternatives to injected therapies to treat all sub-types of HAE in the form of innovative small molecules. HAE is a rare and potentially life-threatening genetic disease which causes debilitating and often painful swelling in various areas of the body and organs, including the airways.  

“We are encouraged by these results to continue development of PHA121 as an oral treatment for hereditary angioedema”, comments Berndt Modig, CEO and co-founder of Pharvaris, in the press release. He adds: “In 2021, we will explore the therapeutic potential of PHA121 for both acute and prophylactic treatment of HAE”. Soft capsules are used for this “highly potent, specific, and orally bioavailable competitive antagonist”.

In addition, Pharvaris is planning to conduct an initial public offering (IPO) before the end of this year. As the US investment group Renaissance Capital has announced, the relevant application has been submitted to the SEC, the agency responsible for monitoring stock market activities in the USA. Pharvaris is looking to raise up to 100 million US dollars from this IPO.